Home / Pharmaceuticals / Mantle Cell Lymphoma Treatment Market By Mechanism Of Action (Bruton’s Tyrosine Kinase Blocker (Ibrutinib), Angiogenesis Inhibitor (Lenalidomide), CD20 Antigen Inhibitor (Rituximab), mTOR Protein Inhibitor (Temsirolimus), Proteasome Inhibitors (Bortezomib), Phase III Drug, Tabular Representation Of Phase II And I Drugs) - Growth, Future Prospects & Competitive Analysis, 2017 – 2025

Mantle Cell Lymphoma Treatment Market By Mechanism Of Action (Bruton’s Tyrosine Kinase Blocker (Ibrutinib), Angiogenesis Inhibitor (Lenalidomide), CD20 Antigen Inhibitor (Rituximab), mTOR Protein Inhibitor (Temsirolimus), Proteasome Inhibitors (Bortezomib), Phase III Drug, Tabular Representation Of Phase II And I Drugs) - Growth, Future Prospects & Competitive Analysis, 2017 – 2025

Published: Dec 2017 | Report Code: 58886-12-17

The World Health Organization has reported the incidence rate of mantle cell lymphoma globally as 0.5 cases per 100,000 people. Mantle cell lymphoma possess an aggressive disease etiology that usually commences with the enlargement of lymph node and progress to metastasis to other organs such as bone marrow, gastrointestinal tract, and liver. Mantle cell lymphoma is resistant to chemotherapy drug treatment and so a targeted treatment approach has been adopted with promising drugs in the product pipeline with better drug efficacy and safety e.g. Zydelig, Gazyva, Abemaciclib and KTE-C19.

To understand the drug regimen used for the treatment of mantle cell lymphoma the drugs segmented on the basis of mechanism of action are Bruton’s Tyrosine Kinase Blocker (ibrutinib), Angiogenesis Inhibitor (lenalidomide), CD20 Antigen Inhibitor (rituximab), mTOR Protein Inhibitor (temsirolimus) and Proteasome Inhibitors (bortezomib). A brief description regarding the market size and forecast is available for the above segment.

To understand the performance of drugs employed for the treatment of mantle cell lymphoma in the regional segments their respective major countries has been considered in the segment.

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Rest of LATAM
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Country cross sectional market estimate and forecast for the geography segment has been included in the scope of the report.

The most important aspect is to understand that a promising pipeline will result in competition among the prominent players to have a significant hold on the mantle cell. In order to understand the competitive environment in the development of drug for the treatment of mantle cell lymphoma we need to cater competitive landscape. Latest merger or acquisition and purchase of promising drug molecules are mentioned in the company profile section. The major players in global mantle cell lymphoma treatment market are Celgene Corporation Abbvie, Inc., Astellas Pharma, Inc., Biogen, Inc., Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline Plc, Amgen, Inc., Gilead Sciences, Inc. Johnson and Johnson and F.Hoffman La Roche Ltd.

Mantle Cell Lymphoma Treatment Market

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Mantle Cell Lymphoma Treatment Market Portraiture
2.1.1. Global Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2016 (Value %)
2.1.2. Global Mantle Cell Lymphoma Treatment Market, by Geography, 2016 (Value %)

Chapter 3. Mantle Cell Lymphoma Treatment Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography
3.6. Top 3 Countries: Global Mantle Cell Lymphoma Treatment Market, 2015-2025 (US$ Mn)
3.7. Competitive Landscape: Global Mantle Cell Lymphoma Treatment Market, by Key Players, 2015-2025 (US$ Mn)

Chapter 4. Global Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2015 – 2025 (US$ Mn)
4.1. Overview
4.2. Attractive Investment Proposition: Global Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2016
4.3. Bruton’s Tyrosine Kinase Blocker (Ibrutinib)
4.4. Angiogenesis Inhibitor (Lenalidomide)
4.5. CD20 Antigen Inhibitor (Rituximab)
4.6. mTOR Protein Inhibitor (Temsirolimus)
4.7. Proteasome Inhibitors (Bortezomib)
4.8. Phase III Drug
4.8.1. Acalabrutinib
4.8.2. Bendamustine/Rituximab/Ibrutinib (Qualitative Information)
4.8.3. Ibrutinib/Venetoclax (Qualitative Information)
4.8.4. Lenalidomide/Rituximab (Qualitative Information)
4.8.5. Rituximab/Bortezomib (Qualitative Information)
4.9. Tabular Representation of Phase II and I Drugs

Chapter 5. Global Mantle Cell Lymphoma Treatment Market, by Geography, 2015 – 2025 (US$ Mn)
5.1. Overview
5.2. North America Mantle Cell Lymphoma Treatment Market Analysis, 2015 – 2025
5.2.1. North America Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2015 – 2025 (US$ Mn)
5.2.2. North America Mantle Cell Lymphoma Treatment Market, by Country, 2015 – 2025 (US$ Mn)
5.3. Europe Mantle Cell Lymphoma Treatment Market Analysis, 2015 – 2025
5.3.1. Europe Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2015 – 2025 (US$ Mn)
5.3.2. Europe Mantle Cell Lymphoma Treatment Market, by Country, 2015 – 2025 (US$ Mn)
5.4. Asia Pacific Mantle Cell Lymphoma Treatment Market Analysis, 2015 – 2025
5.4.1. Asia Pacific Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2015 – 2025 (US$ Mn)
5.4.2. Asia Pacific Mantle Cell Lymphoma Treatment Market, by Country, 2015 – 2025 (US$ Mn)
5.5. Latin America Mantle Cell Lymphoma Treatment Market Analysis, 2015 – 2025
5.5.1. Latin America Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2015 – 2025 (US$ Mn)
5.5.2. Latin America Mantle Cell Lymphoma Treatment Market, by Country, 2015 – 2025 (US$ Mn)
5.6. Middle East & Africa Mantle Cell Lymphoma Treatment Market Analysis, 2015 – 2025
5.6.1. Middle East and Africa Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2015 – 2025 (US$ Mn)
5.6.2. Middle East and Africa Mantle Cell Lymphoma Treatment Market, by Region, 2015 – 2025 (US$ Mn)

Chapter 6. Company Profiles
6.1. Abbvie, Inc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. Key Developments
6.2. Amgen, Inc.
6.3. Astellas Pharma, Inc.
6.4. Biogen, Inc.
6.5. Bayer AG
6.6. Bristol-Myers Squibb Company
6.7. Celgene Corporation
6.8. Eli Lilly and Company
6.9. GlaxoSmithKline Plc
6.10. Gilead Sciences, Inc.
6.11. Johnson and Johnson
6.12. F.Hoffman La Roche Ltd.

List Of Table :

TABLE 1 Global Mantle Cell Lymphoma Treatment Market Portraiture
TABLE 2 Global Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2015 – 2025 (US$ Mn)
TABLE 3 Global Mantle Cell Lymphoma Treatment Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 4 North America Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2015 – 2025 (US$ Mn)
TABLE 5 North America Mantle Cell Lymphoma Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 6 Europe Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2015 – 2025 (US$ Mn)
TABLE 7 Europe Mantle Cell Lymphoma Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 8 Asia Pacific Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2015 – 2025 (US$ Mn)
TABLE 9 Asia Pacific Mantle Cell Lymphoma Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 10 Latin America Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2015 – 2025 (US$ Mn)
TABLE 11 Latin America Mantle Cell Lymphoma Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 12 Middle East And Africa Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2015 – 2025 (US$ Mn)
TABLE 13 Middle East And Africa Mantle Cell Lymphoma Treatment Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 14 Abbvie, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 Amgen, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 Astellas Pharma, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 Biogen, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 Bayer AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 Bristol-Myers Squibb Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 Celgene Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Eli Lilly and Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 GlaxoSmithKline Plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 Gilead Sciences, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 24 Johnson and Johnson: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 25 F.Hoffman La Roche Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)

List Of Figures :

FIG. 1 Mantle Cell Lymphoma Treatment: Market Segmentation
FIG. 2 Global Mantle Cell Lymphoma Treatment Market Share, by Mechanism of Action, 2016 (Value %)
FIG. 3 Global Mantle Cell Lymphoma Treatment Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography
FIG. 5 Market Competition Landscape, by Key Players, 2016
FIG. 6 Global Ibrutinib Market for Mantle Cell Lymphoma Treatment, 2015 – 2025 (US$ Mn)
FIG. 7 Global Lenalidomide Market for Mantle Cell Lymphoma Treatment, 2015 – 2025 (US$ Mn)
FIG. 8 Global Rituximab Market for Mantle Cell Lymphoma Treatment, 2015 – 2025 (US$ Mn)
FIG. 9 Global Temsirolimus Market for Mantle Cell Lymphoma Treatment, 2015 – 2025 (US$ Mn)
FIG. 10 Global Bortezomib Market for Mantle Cell Lymphoma Treatment, 2015 – 2025 (US$ Mn)
FIG. 11 U.S. Mantle Cell Lymphoma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 12 Canada Mantle Cell Lymphoma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 13 U.K. Mantle Cell Lymphoma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 14 Germany Mantle Cell Lymphoma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 15 Rest of Europe Mantle Cell Lymphoma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 16 Japan Mantle Cell Lymphoma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 17 China Mantle Cell Lymphoma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 18 India Mantle Cell Lymphoma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 19 Rest of Asia Pacific Mantle Cell Lymphoma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 20 Brazil Mantle Cell Lymphoma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 21 Mexico Mantle Cell Lymphoma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 22 Rest of Latin America Mantle Cell Lymphoma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 23 GCC Mantle Cell Lymphoma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 24 Rest of Middle East and Africa Mantle Cell Lymphoma Treatment Market, 2015 – 2025 (US$ Mn)

Based on mechanism of action, the mantle cell lymphoma treatment market is categorized into:

  • Bruton’s Tyrosine Kinase Blocker (Ibrutinib)
  • Angiogenesis Inhibitor (Lenalidomide)
  • CD20 Antigen Inhibitor (Rituximab)
  • mTOR Protein Inhibitor (Temsirolimus)
  • Proteasome Inhibitors (Bortezomib)
  • Phase III Drug
    • Acalabrutinib
    • Bendamustine/Rituximab/Ibrutinib (Qualitative Information)
    • Ibrutinib/Venetoclax (Qualitative Information)
    • Lenalidomide/Rituximab (Qualitative Information)
    • Rituximab/Bortezomib (Qualitative Information)
  • Tabular Representation of Phase II and I Drugs

Mantle Cell Lymphoma Treatment Market

Mantle cell lymphoma is distinguished by the overexpression of cyclin D1 which is engaged in the stimulation of cell growth due to the translocation being caused between chromosomes 11 and 14. The occurrence of mantle cell lymphoma is approximately around 3 to 6% of newly diagnosed cases with non-Hodgkin’s lymphoma. It is metastatic in nature with clinical manifestation reported as highly aggressive and involves the extranodal engagement of gastrointestinal tract and bone marrow. Rituximab has been approved as the first line of treatment along with chemotherapy drugs such as cyclophosphamide, doxorubicin, vincristine and prednisone. The dominance of rituximab is due to the increasing number of non-hodgkins patients diagnosed with CD20 antigen considered as marker for mantle cell lymphoma. Obinutuzumab (Roche) will be considered to replace rituximab for the treatment of mantle cell lymphoma. Bortezomib and lenalidomide most likely will be subjected to face generic completion during the forecast period of 2017-2025. Ibrutinib will be showcasing significant growth and set to be the market leader in the treatment of mantle cell lymphoma, due to increasing cases of relapsed mantle cell lymphoma and ability to promote apoptosis of the tumor cells. The prominent players in mantle cell lymphoma treatment market are Bristol-Myers Squibb Company, Abbvie, Inc., Celgene Corporation, Amgen, Inc., Astellas Pharma, Inc., Biogen, Inc., Bayer AG, Eli Lilly and Company, GlaxoSmithKline Plc, Gilead Sciences, Inc. Johnson and Johnson and F.Hoffman La Roche Ltd.

For the purpose of this study, the global mantle cell lymphoma treatment market is categorized into the following regional and country specific markets:

  • North America
    • United States
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Mantle Cell Lymphoma Treatment Market

North America is currently dominating the global mantle cell lymphoma treatment market. According to the research findings of the Leukemia and Lymphoma Society in 2014 there were around 4,200 cases of mantle cell lymphoma. The advancement in the diagnostic procedures has resulted in efficient mapping of mantle cell lymphoma cases in patients suffering with non-hodgkin’s lymphoma benefits the U.S. market. The market growth in Europe is mainly attributed to increase in patients above 60 years of age diagnosed with mantle cell lymphoma. The European Medical Agency provides supportive regulatory environment for the mantle cell lymphoma treatment drugs. Asia Pacific will enjoy impressive market growth due to increasing number of patients suffering with mantle cell lymphoma showing relative association with Borrelia burgdorferi infection and genetic predisposition. The Asian Pacific market will reap the profits from the generic competition which will be faced by bortezomib and lenalidomide during the period 2015-2025. High spending to raise government aided hospitals and research centers to treat blood malignancies drives the growth in Middle East and Africa and Latin America.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients